A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions

Sabine Maier, Christine H Chung, Michael Morse, Thomas Platts-Mills, Leigh Townes, Pralay Mukhopadhyay, Prabhu Bhagavatheeswaran, Jan Racenberg, Ovidiu C Trifan, Sabine Maier, Christine H Chung, Michael Morse, Thomas Platts-Mills, Leigh Townes, Pralay Mukhopadhyay, Prabhu Bhagavatheeswaran, Jan Racenberg, Ovidiu C Trifan

Abstract

Severe infusion reactions (SIRs) at rates of 5% or less are known side effects of biological agents, including mAbs such as cetuximab. There are currently no prospectively validated risk factors to aid physicians in identifying patients who may be at risk of experiencing an SIR following administration of any of these drugs. A retrospective analysis of 545 banked serum or plasma samples from cancer patients participating in clinical trials of cetuximab was designed to evaluate whether the presence of pretreatment IgE antibodies against cetuximab, as determined by a commercially available assay system, is associated with SIRs during the initial cetuximab infusion. Patients with a positive test indicating the presence of pretreatment antibodies had a higher risk of experiencing an SIR; however, at the prespecified cutoff utilized in this analysis, the test has a relatively low-positive predictive value (0.577 [0.369-0.766]) and a negative predictive value of 0.961 (0.912-0.987) in an unselected patient population. Data collected in this large retrospective validation study support prior observations of an association between the presence of pretreatment IgE antibodies cross-reactive with cetuximab and SIRs. Further analysis of the test's ability to predict patients at risk of an SIR would be required before this assay could be used reliably in this patient population.

Keywords: Biomarkers; cetuximab; colorectal neoplasms; head and neck neoplasms; immunoglobulin E; lung neoplasms.

© 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Study schema showing the 545 cetuximab-treated patients from whom banked serum or plasma samples were available. SIR, severe infusion reaction.

References

    1. Herceptin (trastuzumab) [package insert] South San Francisco, CA: Genentech, Inc; 2014.
    1. Rituxan (rituximab) [package insert] South San Francisco, CA: Genentech, Inc; 2013.
    1. Avastin (bevacizumab) [package insert] South San Francisco, CA: Genentech, Inc; 2013.
    1. Remicade (infliximab) [package insert] Horsham, PA: Janssen Biotech, Inc; 2013.
    1. Erbitux (cetuximab) [package insert] Branchburg, NJ, and Princeton, NJ: ImClone, a wholly-owned subsidiary of Eli Lilly and Company and Bristol-Myers Squibb Company; 2004.
    1. Vectibix (panitumumab) [package insert] Thousand Oaks, CA: Amgen Inc; 2013.
    1. Pichler WJ. Drug hypersensitivity reactions: classification and relationship to T-cell activation. In: Pichler WJ, editor. Drug hypersensitivity. Basel, Switzerland: Karger; 2007. pp. 168–189.
    1. O'Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J. Clin. Oncol. 2007;25:3644–3648.
    1. Kiwan EN, Siegel E, Hutchins LF, Maddox A, Govindarajan R, Safar AM, et al. Cetuximab-related infusion reaction rate in cancer patients differs by race [abstract] J. Clin. Oncol. 2011;29(Suppl):e14075. Abstract.
    1. Owera R, Gill A, Haddadin S, Khozouz R. Perry MC. High incidence of hypersensitivity reactions to cetuximab in fusions in mid-Missouri: association with prior history of atopy [abstract] J. Clin. Oncol. 2008;26(Suppl):20747. Abstract.
    1. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N. Engl. J. Med. 2008;358:1109–1117.
    1. Commins SP, James HR, Kelly LA, Pochan SL, Workman LJ, Perzanowski MS, et al. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose. J. Allergy Clin. Immunol. 2011;127:1286–1293.
    1. Commins SP, Satinover SM, Hosen J, Mozena J, Borish L, Lewis BD, et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-α-1,3-galactose. J. Allergy Clin. Immunol. 2009;123:426–433.
    1. Yman L. Standardization of IgE antibody assays. J. Int. Fed. Clin. Chem. 1991;3:198–203.
    1. Yman L. Allergy. In: Wild D, editor. The immunoassay handbook. New York, NY: Nature Publishing Group; 2001. pp. 664–680.
    1. Mariotte D, DuPont B, Gervais R, Galais MP, Laroche D, Tranchant A, et al. Anti-cetuximab IgE ELISA for identification of patients at high risk of cetuximab-induced anaphylaxis. MAbs. 2011;3:396–401.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner